Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Anti-PD-1 Antibody Resistant”

17 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 17 of 17 results

Testing effectiveness (Phase 2)UnknownNCT06509971
What this trial is testing

QL1706 (an Anti-PD-1/CTLA-4 Combined Antibody) Combined With Albumin-bound Paclitaxel and Bevacizumab in the Treatment of Platinum-resistant Recurrent Ovarian Cancer

Who this might be right for
Platinum-resistant Recurrent Ovarian Cancer
West China Second University Hospital 39
Early research (Phase 1)Ended earlyNCT04060342
What this trial is testing

GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma

Who this might be right for
Pancreatic AdenocarcinomaEsophageal AdenocarcinomaEsophageal Squamous Cell Carcinoma+11 more
GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. 61
Testing effectiveness (Phase 2)Active Not RecruitingNCT06784648
What this trial is testing

Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma

Who this might be right for
Melanoma MetastaticMelanoma of SkinMelanoma BRAF V600E/K Mutated+7 more
BioInvent International AB 35
Testing effectiveness (Phase 2)Study completedNCT02129556
What this trial is testing

Anti-PD-1 Monoclonal Antibody in Advanced, Trastuzumab-resistant, HER2-positive Breast Cancer

Who this might be right for
Metastatic Breast Cancer
ETOP IBCSG Partners Foundation 58
Testing effectiveness (Phase 2)Ended earlyNCT03729596
What this trial is testing

MGC018 With or Without MGA012 in Advanced Solid Tumors

Who this might be right for
Squamous Cell Carcinoma of Head and NeckTriple Negative Breast CancerMelanoma+3 more
MacroGenics 143
Testing effectiveness (Phase 2)UnknownNCT06156878
What this trial is testing

PD-1 Inhibitor Plus Anti-EGFR Therapy And Radiotherapy in Locally Advanced NPC Resistant to Induction Chemotherapy

Who this might be right for
Nasopharyngeal Carcinoma
Fudan University 41
Testing effectiveness (Phase 2)Looking for participantsNCT03591276
What this trial is testing

Phase 1b Study of Pegylated Liposomal Doxorubicin and Pembrolizumab in Endocrine-resistant Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Shaare Zedek Medical Center 15
Testing effectiveness (Phase 2)Active Not RecruitingNCT03607890
What this trial is testing

Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor

Who this might be right for
Refractory MSI - H Solid Tumors Prior of PD-(L) 1 TherapyMSI-H Tumors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 38
Early research (Phase 1)Ended earlyNCT03716596
What this trial is testing

SBRT and Anti-programmed Cell Death Protein 1(Anti-PD-1) in Late Stage or Recurrent Pancreatic Cancer Patients

Who this might be right for
Pancreatic Cancer
Second Affiliated Hospital, Zhejiang University, School of Medicine 8
Testing effectiveness (Phase 2)UnknownNCT04514081
What this trial is testing

The Clinical Trial of Chidamide+Decitabine+Camrelizumab Versus Decitabine+Camrelizumab in Anti-PD-1 Antibody Resistant Patients With Classical Hodgkin Lymphoma.

Who this might be right for
Hodgkin LymphomaAnti-PD-1 Antibody Resistant
Chinese PLA General Hospital 200
Testing effectiveness (Phase 2)Ended earlyNCT01420965
What this trial is testing

Sipuleucel-T, CT-011, and Cyclophosphamide for Advanced Prostate Cancer

Who this might be right for
Prostatic Neoplasms
Augusta University 7
Early research (Phase 1)Looking for participantsNCT06826768
What this trial is testing

A Ph Ib Study of REGN5678 Plus Cemiplimab in Patients With mCRPC

Who this might be right for
Prostate Cancer
M.D. Anderson Cancer Center 60
Testing effectiveness (Phase 2)Ended earlyNCT03041181
What this trial is testing

Single Agent Chemotherapy +/- Nivolumab in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor

Who this might be right for
Non-Squamous Non-Small Cell Lung Cancer (NSCLC)Adenocarcinoma of the LungLung Cancer+1 more
Nasser Hanna, M.D. 3
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05732662
What this trial is testing

SBRT Combined With AK104 to Treatment Relapsed or Metastatic ESCC

Who this might be right for
Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
The First People's Hospital of Changzhou 25
Very early researchActive Not RecruitingNCT06866548
What this trial is testing

Safety and Efficacy Evaluation of Anti IGF-1R Monoclonal Antibody Combined With Anti-PD-1 Monoclonal Antibody in Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer

Who this might be right for
mCRPC
Shanghai Changzheng Hospital 7
Testing effectiveness (Phase 2)Looking for participantsNCT07070479
What this trial is testing

Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial

Who this might be right for
Recurrent or Metastatic Nasopharyngeal Carcinoma
Ming-Yuan Chen 208
Testing effectiveness (Phase 2)UnknownNCT06259721
What this trial is testing

Anti-PD1 Monoclonal Antibody Combined With Nimotuzumab and Capecitabine in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma

Who this might be right for
Nasopharyngeal Carcinoma
Jiangxi Provincial Cancer Hospital 22